Page last updated: 2024-12-10

diclosulam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diclosulam: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081304
CHEMBL ID1873575
CHEBI ID81984
SCHEMBL ID116344
MeSH IDM0372199

Synonyms (34)

Synonym
6x5do0i08z ,
unii-6x5do0i08z
NCGC00163839-01
n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide
diclosulam
145701-21-9
(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonamide, n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-
diclosulam [iso]
n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonamide
NCGC00163839-02
n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide
NCGC00163839-03
strongarm
n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonamide
C18821
dtxsid4034528 ,
tox21_300765
cas-145701-21-9
dtxcid2014528
NCGC00254669-01
FT-0631172
AKOS015899984
diclosulam [mi]
2',6'-dichloro-5-ethoxy-7-fluoro(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonanilide
xde-564
SCHEMBL116344
CHEBI:81984 ,
CHEMBL1873575
[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide, n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-
J-008139
mfcd04972567
Q27155672
spider (herbicide); strongarm; xde 564
diclosulam 100 microg/ml in acetonitrile

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.13060.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency28.92400.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency46.12170.000221.22318,912.5098AID1259243; AID743036
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency48.55770.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.55770.001022.650876.6163AID1224838
retinoid X nuclear receptor alphaHomo sapiens (human)Potency36.75370.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency39.78240.001530.607315,848.9004AID1224841; AID1224842; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency44.80320.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency2.75360.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency13.49870.001019.414170.9645AID588536; AID743094; AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.87240.023723.228263.5986AID743223
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.33650.001723.839378.1014AID743083
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency61.13060.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's4 (57.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.30 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index79.80 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (54.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]